FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565176477> ?p ?o ?g. }

• W2565176477 endingPage "11506" @default.
• W2565176477 startingPage "11489" @default.
• W2565176477 abstract "// Jian Sun 1, * , Xuan Liu 2, * , Hong Gao 1 , Long Zhang 1 , Qing Ji 2 , Ziyuan Wang 1 , Lihong Zhou 2 , Yan Wang 3 , Hua Sui 2 , Zhongze Fan 1 , Qi Li 2 1 Interventional Cancer Institute of Integrative Medicine & Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China 2 Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China 3 Cancer Institute of Traditional Chinese Medicine & Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China * These authors have contributed equally to this work Correspondence to: Qi Li, email: Lzwf@hotmail.com Keywords: colorectal cancer, BMP, CHRDL2, proliferation, apoptosis Received: July 06, 2016      Accepted: November 07, 2016      Published: December 20, 2016 ABSTRACT Bone morphogenetic proteins (BMPs) both promote and suppress tumorigenesis, and multiple BMP antagonists reportedly contribute to cancer progression. In this study, we demonstrated that the BMP antagonist Chordin-like 2 (CHRDL2) is upregulated in colorectal cancer (CRC) tissues, and that CHRDL2 levels correlate with clinical features of CRC patients, including tumor size, TNM staging, and tumor differentiation. In addition, survival rate and Cox proportional hazards model analyses showed that high CHRDL2 levels correlate with a poor prognosis in CRC. Moreover, CHRDL2 promoted CRC cell proliferation in vitro and in vivo , perhaps through up-regulation of Cyclin D1 and down-regulation of P21. Co-immunoprecipitation assays showed that CHRDL2 bound to BMPs, which inhibited p-Smad1/5, thereby promoting CRC cell proliferation and inhibiting apoptosis. These results suggest CHRDL2 could serve as a biomarker of poor prognosis in CRC, and provide evidence that CHRDL2 acts as an oncogene in human CRC, making it a novel potential therapeutic target." @default.
• W2565176477 created "2017-01-06" @default.
• W2565176477 creator A5002897023 @default.
• W2565176477 creator A5003642180 @default.
• W2565176477 creator A5020746135 @default.
• W2565176477 creator A5028710085 @default.
• W2565176477 creator A5038221217 @default.
• W2565176477 creator A5051322557 @default.
• W2565176477 creator A5054844187 @default.
• W2565176477 creator A5069028088 @default.
• W2565176477 creator A5070016516 @default.
• W2565176477 creator A5070110008 @default.
• W2565176477 creator A5075059321 @default.
• W2565176477 date "2016-12-20" @default.
• W2565176477 modified "2023-10-17" @default.
• W2565176477 title "Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis" @default.
• W2565176477 cites W1514397065 @default.
• W2565176477 cites W1820818689 @default.
• W2565176477 cites W1968768080 @default.
• W2565176477 cites W1970787607 @default.
• W2565176477 cites W1972571056 @default.
• W2565176477 cites W1978828082 @default.
• W2565176477 cites W1979914609 @default.
• W2565176477 cites W1984000404 @default.
• W2565176477 cites W1989451500 @default.
• W2565176477 cites W1991095294 @default.
• W2565176477 cites W1995773697 @default.
• W2565176477 cites W2002114387 @default.
• W2565176477 cites W2013269714 @default.
• W2565176477 cites W2013960424 @default.
• W2565176477 cites W2015071134 @default.
• W2565176477 cites W2015777584 @default.
• W2565176477 cites W2023906737 @default.
• W2565176477 cites W2032790578 @default.
• W2565176477 cites W2033700197 @default.
• W2565176477 cites W2036887542 @default.
• W2565176477 cites W2039849446 @default.
• W2565176477 cites W2040471138 @default.
• W2565176477 cites W2041430674 @default.
• W2565176477 cites W2049451031 @default.
• W2565176477 cites W2051190668 @default.
• W2565176477 cites W2056973997 @default.
• W2565176477 cites W2058378456 @default.
• W2565176477 cites W2059297110 @default.
• W2565176477 cites W2059660194 @default.
• W2565176477 cites W2062532376 @default.
• W2565176477 cites W2063463246 @default.
• W2565176477 cites W2067553572 @default.
• W2565176477 cites W2070853081 @default.
• W2565176477 cites W2074296490 @default.
• W2565176477 cites W2086801198 @default.
• W2565176477 cites W2090673274 @default.
• W2565176477 cites W2096425114 @default.
• W2565176477 cites W2097924745 @default.
• W2565176477 cites W2104297850 @default.
• W2565176477 cites W2104890494 @default.
• W2565176477 cites W2106787323 @default.
• W2565176477 cites W2118884695 @default.
• W2565176477 cites W2121086400 @default.
• W2565176477 cites W2122831215 @default.
• W2565176477 cites W2126762584 @default.
• W2565176477 cites W2132135140 @default.
• W2565176477 cites W2132790765 @default.
• W2565176477 cites W2137585125 @default.
• W2565176477 cites W2139752629 @default.
• W2565176477 cites W2139963781 @default.
• W2565176477 cites W2144895630 @default.
• W2565176477 cites W2146690661 @default.
• W2565176477 cites W2153243072 @default.
• W2565176477 cites W2154937094 @default.
• W2565176477 cites W2156898371 @default.
• W2565176477 cites W2157197884 @default.
• W2565176477 cites W2166774172 @default.
• W2565176477 cites W2197188550 @default.
• W2565176477 cites W2220397872 @default.
• W2565176477 cites W4245862414 @default.
• W2565176477 doi "https://doi.org/10.18632/oncotarget.14039" @default.
• W2565176477 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5355280" @default.
• W2565176477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28009989" @default.
• W2565176477 hasPublicationYear "2016" @default.
• W2565176477 type Work @default.
• W2565176477 sameAs 2565176477 @default.
• W2565176477 citedByCount "10" @default.
• W2565176477 countsByYear W25651764772019 @default.
• W2565176477 countsByYear W25651764772020 @default.
• W2565176477 countsByYear W25651764772021 @default.
• W2565176477 countsByYear W25651764772022 @default.
• W2565176477 countsByYear W25651764772023 @default.
• W2565176477 crossrefType "journal-article" @default.
• W2565176477 hasAuthorship W2565176477A5002897023 @default.
• W2565176477 hasAuthorship W2565176477A5003642180 @default.
• W2565176477 hasAuthorship W2565176477A5020746135 @default.
• W2565176477 hasAuthorship W2565176477A5028710085 @default.
• W2565176477 hasAuthorship W2565176477A5038221217 @default.
• W2565176477 hasAuthorship W2565176477A5051322557 @default.
• W2565176477 hasAuthorship W2565176477A5054844187 @default.
• W2565176477 hasAuthorship W2565176477A5069028088 @default.
• W2565176477 hasAuthorship W2565176477A5070016516 @default.

• next